Vaxart Inc (VXRT)
7.81
-0.93 -10.64%
NASDAQ
Jun 15, 20:00
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 1.65M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -0.47 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -46.93M |
| Profitability | |
| Gross Profit Margin (Quarterly) | -- |
| Profit Margin (Quarterly) | -3.16K% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0.00% |
| Price and Valuation | |
| Market Cap | 954.92M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 482.37 |
| PE Ratio | -- |
| Price to Book Value | 5.418 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow (Quarterly) | -17.21M |
| Return on Equity | Upgrade |
View All VXRT News
News
-
WireHeadlineTime (ET)
-
Yahoo06/15 11:50
-
Yahoo06/15 09:56
-
PR Newswire06/14 08:30
-
Yahoo06/14 07:35
-
MT Newswires06/11 14:16
-
SA Breaking News06/11 12:42
-
SA Breaking News06/11 12:05
-
Yahoo06/11 12:01
-
SA Breaking News06/11 11:00
-
PR Newswire06/11 09:31
-
Yahoo06/11 08:25
-
MT Newswires06/11 06:13
-
Yahoo06/10 11:59
-
Yahoo06/08 05:51
-
Yahoo06/07 15:13
-
Globe Newswire06/07 09:00
-
Yahoo05/29 15:49
-
Globe Newswire05/27 08:00
-
SA Breaking News05/26 07:10
-
Yahoo05/17 09:53
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 08/06/2021 | Earnings Results | Q2 2021 Earnings Results |
| 02/25/2021 | Earnings Results | Q4 2020 Earnings Results |
| 11/12/2020 | Earnings Results | Q3 2020 Earnings Results |
| 08/06/2020 | Earnings Results | Q2 2020 Earnings Results |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- Description: Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
- URL: https://www.vaxart.com
- Investor Relations URL: https://investors.vaxart.com/
- HQ State/Province: California
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Blend
- Next Earnings Release: Aug. 06, 2021
- Last Earnings Release: Feb. 25, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: Nov. 09, 2012
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 7.81 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| XBI | SPDR® S&P Biotech ETF | 0.89% |
| LABU | Direxion Daily S&P Biotech Bull 3X ETF | 0.49% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- VXRT Tweets Stocktwits
Advertisement
